• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Teva launches generic EpiPen at the same price as existing device

November 29, 2018 By Sarah Faulkner

Teva Pharmaceutical logo - updatedTeva (NYSE:TEVA) this week launched its generic version of Mylan‘s (NSDQ:MYL) EpiPen auto-injector and announced that it would sell the emergency allergy therapy for $300 – the same price as Mylan’s own generic EpiPen product.

The price for Teva’s product inspired some head-scratching among patient advocates and healthcare professionals. After all, when the FDA first approved Teva’s generic EpiPen, the agency highlighted the notion that boosting competition with generics would ultimately make the product more accessible to a general population. But, at the same price as Mylan’s discounted EpiPen, some are wondering how Teva’s product will reach patients who couldn’t afford Mylan’s device.

Mylan faced an enormous backlash in 2016 when reports showed that the company hiked the price of its EpiPen device by nearly 500% since 2007. In response to widespread criticism, Mylan launched a generic EpiPen in Dec. 2016, pricing it at $300 per two-pack – a 50% discount compared to the branded product.

Gottlieb reportedly issued a statement over the latest news from Teva, writing that the FDA “cannot control commercial decisions on pricing” and that “we have found that having three or more generic competitors brings prices down more sharply than with only one or two generic competitors.”

“We’re pleased to provide access to Epinephrine Injection (Auto-Injector) for patients who may experience life-threatening allergic emergencies and we’re fully dedicated toward ensuring additional supply in 2019,” EVP & head of Teva’s North America commercial division, Brendan O’Grady, said in prepared remarks.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Regulatory/Compliance, Technology, Wall Street Beat Tagged With: Mylan, Teva Pharmaceuticals

IN CASE YOU MISSED IT

  • Another BD Alaris infusion pump recall is Class I
  • Amgen completes $1.9B acquisition of Five Prime Therapeutics
  • Oncopeptides seeks EU marketing authorization for multiple myeloma treatment
  • Horizon touts data from trials for thyroid eye disease infusion treatment
  • Genentech touts study results for spinal muscular atrophy drug in babies

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS